A case of Fanconi syndrome as a complication of treatment with a checkpoint inhibitor in a patient with hepatocellular carcinoma

Mohammad Tinawi ¹, Bahar Bastani ² *

Cited by CrossRef: 7

1- Catalano M, Roviello G, Galli I, Santi R, Nesi G. Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. Front Med. 2022;9 [Crossref]

2- Uppal N, Workeneh B, Rondon-Berrios H, Jhaveri K. Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy. CJASN. 2022;17(6):922 [Crossref]

3- Georgery M, Ram A, Van Meerhaeghe T, Drowart A, Clause A, Dal Lago L, Rouvière H. Occurrence of Fatal Tubulopathy in an Old, Fit Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report. Case Rep Oncol. 2024;17(1):239 [Crossref]

4- Fujioka H, Kakeshita K, Imamura T, Arisawa Y, Yokoyama S, Yamazaki H, Koike T, Minamisaka T, Hirabayashi K, Kinugawa K. Pembrolizumab-induced Acute Tubulointerstitial Nephritis Accompanying Fanconi Syndrome and Type 1 Renal Tubular Acidosis. Intern Med. 2024;63(4):533 [Crossref]

5- Tinawi M, Bastani B. Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond. 2020; [Crossref]

6- Nivolumab/sorafenib. Reactions Weekly. 2020;1799(1):296 [Crossref]

7- Adhikari S, Mamlouk O, Rondon-Berrios H, Workeneh B. Hypophosphatemia in cancer patients. 2021;14(11):2304 [Crossref]